Acidic domain is indispensable for MDM2 to negatively regulate the acetylation of p53

Biochemical and Biophysical Research Communications

Volumn 374, Issue 3, 2008, Pages 437-441

  Wang, Qian ^a   Yang, Ying ^a   Wang, Lan ^a   Zhang, Ping zhao ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Acetylation; Acidic domain; HDAC1; MDM2; p300; p53

Indexed keywords

ACYLTRANSFERASE; HISTONE DEACETYLASE 1; PROTEIN MDM2; PROTEIN P53;

ACETYLATION; ACIDITY; ARTICLE; CONTROLLED STUDY; DEACETYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; RING FINGER MOTIF; UBIQUITINATION; WESTERN BLOTTING;

ACETYLATION; AMINO ACID SEQUENCE; HELA CELLS; HISTONE DEACETYLASES; HUMANS; MOLECULAR SEQUENCE DATA; P300-CBP TRANSCRIPTION FACTORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48849114168     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.07.038     Document Type: Article

References (25)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
2. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
3. Brooks C.L., and Gu W. Ubiquitination phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
4. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
5. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3 (2003) 102-109
6. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., and Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19 (1999) 1202-1209
7. Luo J., Li M., Tang Y., Laszkowska M., Roeder R.G., and Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101 (2004) 2259-2264
8. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., and Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12 (1998) 2831-2841
9. Iwakuma T., Parant J.M., Fasulo M., Zwart E., Jacks T., de Vries A., and Lozano G. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 23 (2004) 7644-7650
10. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13 (2003) 49-58
11. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., and Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275 (2000) 8945-8951
12. Honda R., and Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19 (2000) 1473-1476
13. Kawai H., Wiederschain D., and Yuan Z.M. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell. Biol. 23 (2003) 4939-4947
14. Meulmeester E., Frenk R., Stad R., de Graaf P., Marine J.C., Vousden K.H., and Jochemsen A.G. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol. 23 (2003) 4929-4938
15. Wallace M., Worrall E., Pettersson S., Hupp T.R., and Ball K.L. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23 (2006) 251-263
16. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., and Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21 (2002) 6236-6245
17. Li M., Luo J., Brooks C.L., and Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277 (2002) 50607-50611
18. Jin Y., Zeng S.X., Dai M.S., Yang X.J., and Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 277 (2002) 30838-30843
19. Kobet E., Zeng X., Zhu Y., Keller D., and Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA 97 (2000) 12547-12552
20. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., and Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20 (2001) 1331-1340
21. Luo J., Su F., Chen D., Shiloh A., and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408 (2000) 377-381
22. Grossman S.R., Perez M., Kung A.L., Joseph M., Mansur C., Xiao Z.X., Kumar S., Howley P.M., and Livingston D.M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2 (1998) 405-415
23. Meek D.W., and Knippschild U. Posttranslational modification of MDM2. Mol. Cancer Res. 1 (2003) 1017-1026
24. Ma J., Martin J.D., Zhang H., Auger K.R., Ho T.F., Kirkpatrick R.B., Grooms M.H., Johanson K.O., Tummino P.J., Copeland R.A., and Lai Z. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45 (2006) 9238-9245
25. Yu G.W., Rudiger S., Veprintsev D., Freund S., Fernandez-Fernandez M.R., and Fersht A.R. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. USA 103 (2006) 1227-1232